Roberto Rodríguez Jiménez-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Association between neutrophil to lymphocyte ratio and inflammatory biomarkers in patients with a first episode of psychosis

    Journal of Psychiatric Research, Vol. 172, pp. 334-339

  2. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

    European Neuropsychopharmacology, Vol. 85, pp. 66-77

2023

  1. Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120

  2. The polygenic basis of relapse after a first episode of schizophrenia

    European Neuropsychopharmacology, Vol. 75, pp. 80-92

2022

  1. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

    Schizophrenia, Vol. 8, Núm. 1

  2. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

    European Neuropsychopharmacology, Vol. 57, pp. 105-117

2021

  1. A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis

    Schizophrenia Research, Vol. 236, pp. 19-28

2020

  1. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2019

  1. Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis

    European Child and Adolescent Psychiatry, Vol. 28, Núm. 10, pp. 1395-1405

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

2016

  1. BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics after 1 Year

    Schizophrenia Bulletin, Vol. 42, Núm. 1, pp. 142-151

2014

  1. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178

  2. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia

    Schizophrenia Bulletin, Vol. 40, Núm. 2, pp. 376-387

  3. Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain

    Schizophrenia Research, Vol. 159, Núm. 1, pp. 107-113

2013

  1. Peripheral endocannabinoid system dysregulation in first-episode psychosis

    Neuropsychopharmacology, Vol. 38, Núm. 13, pp. 2568-2577